NASDAQ:BIOL BIOLASE (BIOL) Stock Forecast, Price & News $0.08 -0.01 (-10.96%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$0.07▼$0.0950-Day Range$0.08▼$0.3952-Week Range$0.07▼$5.94Volume11.07 million shsAverage Volume2.38 million shsMarket Capitalization$2.54 millionP/E RatioN/ADividend YieldN/APrice Target$5.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BIOLASE MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6,827.3% Upside$5.63 Price TargetShort InterestHealthy3.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.27Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.63, BIOLASE has a forecasted upside of 6,827.3% from its current price of $0.08.Amount of Analyst CoverageBIOLASE has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.69% of the float of BIOLASE has been sold short.Short Interest Ratio / Days to CoverBIOLASE has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BIOLASE has recently increased by 4.40%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBIOLASE does not currently pay a dividend.Dividend GrowthBIOLASE does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOL. Previous Next 2.1 News and Social Media Coverage News SentimentBIOLASE has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for BIOLASE this week, compared to 2 articles on an average week.Search Interest15 people have searched for BIOL on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days.MarketBeat Follows8 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIOLASE insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.52% of the stock of BIOLASE is held by insiders.Percentage Held by InstitutionsOnly 20.68% of the stock of BIOLASE is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOLASE is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOLASE is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBIOLASE has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BIOLASE (NASDAQ:BIOL) StockBIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.Read More Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOL Stock News HeadlinesJune 5, 2023 | finance.yahoo.comBIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCKJune 5, 2023 | marketwatch.comBiolase to Cut 20% of WorkforceJune 5, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 5, 2023 | msn.comBIOLASE to cut 20% of US workforce to achieve sales and profitability goalsJune 3, 2023 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.comJune 1, 2023 | nasdaq.comLake Street Maintains Biolase (BIOL) Buy RecommendationMay 31, 2023 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) PT Lowered to $1.50 at Lake Street CapitalMay 29, 2023 | americanbankingnews.comInsider Buying: BIOLASE, Inc. (NASDAQ:BIOL) Major Shareholder Acquires $797,837.91 in StockJune 5, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 26, 2023 | finance.yahoo.comBIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and WarrantsMay 25, 2023 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.comMay 24, 2023 | marketwatch.comBiolase Hits 52-Week Low of 7 Cents After Offering PricesMay 24, 2023 | benzinga.comBiolase shares are trading lower after the company announced the pricing of a $4.5 million underwritten public offering.May 24, 2023 | finance.yahoo.comBIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and WarrantsMay 17, 2023 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.comMay 13, 2023 | marketwatch.comGlobal Electronic Caries Monitors (ECM) Market Size 2023-2031 Technological Innovations by Absolute Reports | with [119 Pages]May 11, 2023 | finance.yahoo.comBIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023May 10, 2023 | msn.comEarnings Outlook For BiolaseMay 10, 2023 | markets.businessinsider.comBiolase earnings: here's what Wall Street expectsMay 10, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)May 10, 2023 | marketwatch.comLaser Medical Instrument Market Size, Business Segments, Innovative Strategies And Outlook by 2030| El.En., Lumenis, BIOLASEMay 9, 2023 | americanbankingnews.comBIOLASE (BIOL) Scheduled to Post Quarterly Earnings on ThursdayMay 4, 2023 | finance.yahoo.comBIOLASE TO REPORT FIRST QUARTER 2023 RESULTS ON MAY 11, 2023April 22, 2023 | marketwatch.comGlobal Dental Products Market by [2023-2029] with Revenue OutsourcingApril 15, 2023 | americanbankingnews.comShort Interest in BIOLASE, Inc. (NASDAQ:BIOL) Increases By 127.0%April 9, 2023 | marketwatch.comDental Hand Instruments Market Facts and Figures By 2030April 8, 2023 | marketwatch.comSemiconductor Laser Therapeutic Equipment Market Demand by 2030See More Headlines BIOL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOL Company Calendar Last Earnings3/28/2023Today6/05/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CUSIPN/A CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees158Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.63 High Stock Price Forecast$14.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+6,827.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,630,000.00 Net Margins-60.92% Pretax Margin-60.73% Return on Equity-244.91% Return on Assets-68.35% Debt Debt-to-Equity Ratio1.53 Current Ratio1.68 Quick Ratio0.75 Sales & Book Value Annual Sales$48.46 million Price / Sales0.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.13Miscellaneous Outstanding Shares31,300,000Free Float31,139,000Market Cap$2.54 million OptionableNot Optionable Beta1.37 Key ExecutivesJohn R. BeaverPresident, Chief Executive Officer & DirectorSteven SandorChief Operating OfficerJennifer BrightonChief Financial OfficerRussell MorrowChief Dental OfficerWilliam E. BrownVice President-Innovation & Business DevelopmentKey CompetitorsThermoGenesisNASDAQ:THMOGRI BioNASDAQ:GRISenesTechNASDAQ:SNESPolarityTENASDAQ:PTETRxADE HEALTHNASDAQ:MEDSView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 95,789 shares on 5/12/2023Ownership: 0.527%Perkins Capital Management Inc.Bought 2,677,285 shares on 5/9/2023Ownership: 10.344%Education Foundation SchulerBought 1,307,931 shares on 2/11/2023Total: $797,837.91 ($0.61/share)Jonathan T Md LordSold 3,537 sharesTotal: $2,652.75 ($0.75/share)View All Insider TransactionsView All Institutional Transactions BIOL Stock - Frequently Asked Questions Should I buy or sell BIOLASE stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOL shares. View BIOL analyst ratings or view top-rated stocks. What is BIOLASE's stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month price targets for BIOLASE's shares. Their BIOL share price forecasts range from $1.50 to $14.00. On average, they anticipate the company's share price to reach $5.63 in the next year. This suggests a possible upside of 6,827.3% from the stock's current price. View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts. How have BIOL shares performed in 2023? BIOLASE's stock was trading at $0.65 on January 1st, 2023. Since then, BIOL stock has decreased by 87.5% and is now trading at $0.0812. View the best growth stocks for 2023 here. When is BIOLASE's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our BIOL earnings forecast. How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) announced its earnings results on Tuesday, March, 28th. The medical technology company reported ($1.28) earnings per share (EPS) for the quarter. The medical technology company earned $14.05 million during the quarter. BIOLASE had a negative trailing twelve-month return on equity of 244.91% and a negative net margin of 60.92%. When did BIOLASE's stock split? BIOLASE's stock reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What guidance has BIOLASE issued on next quarter's earnings? BIOLASE issued an update on its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $60.58M-, compared to the consensus revenue estimate of $59.91 million. What is John R. Beaver's approval rating as BIOLASE's CEO? 4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS). What is BIOLASE's stock symbol? BIOLASE trades on the NASDAQ under the ticker symbol "BIOL." Who are BIOLASE's major shareholders? BIOLASE's stock is owned by many different retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (10.34%) and Renaissance Technologies LLC (0.53%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg. View institutional ownership trends. How do I buy shares of BIOLASE? Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BIOLASE's stock price today? One share of BIOL stock can currently be purchased for approximately $0.08. How much money does BIOLASE make? BIOLASE (NASDAQ:BIOL) has a market capitalization of $2.54 million and generates $48.46 million in revenue each year. The medical technology company earns $-28,630,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis. How many employees does BIOLASE have? The company employs 158 workers across the globe. How can I contact BIOLASE? BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677. This page (NASDAQ:BIOL) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.